Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors

C. Bonnefin(Centre Hospitalier Universitaire de Bordeaux), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), S. Prey(Centre Hospitalier Universitaire de Bordeaux), S. Schneider(Centre Hospitalier Universitaire de Bordeaux), T Ferte(Centre Hospitalier Universitaire de Bordeaux), M. Beylot‐Barry, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), E. Gérard(Université de Bordeaux), S. Pédeboscq(Centre Hospitalier Universitaire de Bordeaux), O Ducharme(Centre Hospitalier Universitaire de Bordeaux), M. Guicheney(Centre Hospitalier Universitaire de Bordeaux)
European Journal of Cancer
January 18, 2025
10.1016/j.ejca.2025.115223
Cited by 5

Related Papers

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k